Antibody-Drug Conjugates (ADCs): Engineering the Next Generation

What Are Antibody-Drug Conjugates?

Antibody-drug conjugates (ADCs) are targeted cancer therapeutics that combine the specificity of monoclonal antibodies (mAbs) with the cell-killing potency of cytotoxic drugs. An ADC consists of three components: a monoclonal antibody (targeting cancer-specific antigens), a cytotoxic payload (typically 100-1000x more potent than standard chemotherapy), and a chemical linker connecting them. The antibody delivers the payload specifically to cancer cells, minimizing systemic toxicity.

As of 2024, 14 ADCs have received FDA approval, with Enhertu (trastuzumab deruxtecan) representing a breakthrough in HER2-low breast cancer. The ADC market is one of the fastest-growing segments in oncology, projected to reach $30 billion by 2030. Next-generation ADCs are addressing first-generation limitations through site-specific conjugation, novel payloads, and AI-driven optimization.

Data: ADC Market and Clinical Landscape

How: Next-Generation ADC Engineering Pipeline

Step 1: Target and Antibody Selection

1. Select tumor-specific antigen with:
   • High expression on tumor, low on healthy tissue
   • Internalization upon antibody binding
   • Uniform expression across tumor
2. Develop or select monoclonal antibody:
   • High affinity (Kd < 1 nM)
   • Good internalization rate
   • Low immunogenicity (humanized or fully human)
3. Optimize antibody format (IgG1 vs. IgG4, fragment vs. full-length)

Step 2: Payload Selection

1. Microtubule inhibitors: MMAE, MMAF (auristatins); DM1, DM4 (maytansinoids)
2. DNA-damaging agents: Calicheamicin, duocarmycin, PBD dimers
3. Topoisomerase I inhibitors: DXd (deruxtecan)—enables bystander effect
4. Novel payloads: RNA polymerase inhibitors, immunostimulatory payloads
5. Optimize potency (IC50 < 1 nM) and physicochemical properties (membrane permeability for bystander effect)

Step 3: Linker Design

1. Cleavable linkers:
   • Protease-cleavable (valine-citrulline, cleaved by cathepsin B)
   • Acid-labile (hydrazone, cleaved in endosome pH)
   • Disulfide (cleaved by intracellular glutathione)
2. Non-cleavable linkers: Payload released after antibody degradation (no bystander effect)
3. Optimize linker stability in plasma (half-life > 7 days) and cleavage efficiency in cells

Step 4: Conjugation Technology

1. First-generation (lysine/cysteine): Heterogeneous DAR (2-8), mixture of species
2. Site-specific conjugation:
   • THIOMAB (engineered cysteines): Homogeneous DAR
   • Enzymatic (Sortase A, transglutaminase): Precise site
   • Click chemistry (azide-alkyne): Bio-orthogonal
   • Glycan engineering: Conjugation at Fc glycans
3. Optimize DAR for therapeutic index (typically DAR 4 for most ADCs)

Step 5: AI-Driven Optimization

1. In silico modeling of ADC pharmacokinetics (multi-compartment PBPK)
2. Machine learning prediction of:
   • Optimal DAR for each target
   • Linker stability in different tissues
   • Bystander effect magnitude
   • Immunogenicity risk
3. Generative AI for novel linker-payload designs
4. Patient stratification using AI biomarker models

Comparison: ADC Generations

Summary: Key Takeaways

1. ADCs combine antibody specificity with cytotoxic potency, with 14 FDA approvals and 200+ in development.
2. Next-generation ADCs feature site-specific conjugation, novel payloads (topoisomerase I inhibitors), and optimized linkers.
3. Enhertu (trastuzumab deruxtecan) expanded the addressable patient population to HER2-low tumors.
4. The bystander effect enhances efficacy in heterogeneous tumors but must be carefully managed for toxicity.
5. AI is increasingly used for DAR optimization, linker design, and patient stratification.

References

1. Drago, J.Z. et al. "Unlocking the potential of antibody-drug conjugates for cancer therapy." Nature Reviews Clinical Oncology (2024).
2. Khongorzul, P. et al. "Antibody-Drug Conjugates: A Comprehensive Review." Molecular Cancer Research 18, 3-19 (2020).
3. Modi, S. et al. "Trastuzumab Deruxtecan in Previously Treated HER2-Low Breast Cancer." NEJM 387, 9-20 (2022).
4. Beck, A. et al. "Strategies and challenges for the next generation of antibody-drug conjugates." Nature Reviews Drug Discovery (2023).
5. FDA. "Antibody-Drug Conjugates: Chemistry, Manufacturing, and Controls." Guidance (2024).